Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (248)	7/13/2004 9:19:11 PM
From: tuck	Read Replies (1) \| Respond to of 510

>>heightened biomarker discovery/analysis at core mass spec labs.<< It's there, though I haven't heard of anyone in a core proteomics facility commercializing patterns of multiple biomarkers yet. While it's possible to actually to do the commerical tests on a Ciphergen system in a clinical lab, you sure wouldn't do that with standard mass specs. They'd go straight to ELISA or something with whatever pattern they came up with. The analogy has been made here before: Mainframe versus PC. Ciphergen sells the PC that lots of folks can use. Others sell mass specs for use in core facilities that only expensive analytical chemists can use. Both have their place. Anyhow, I know Ciphergen has been patenting various molecules -- lots of them -- as biomarkers, so they may have a head start in IP? I have to agree that Rich selling isn't a great thing. I imagine he would have sold earlier, but it would have been trading on inside info regarding the miss, so he had to wait. Haven't checked on his salary recently . . . it would be good to see some buying here, huh? Cheers, Tuck